NCT06559189View on ClinicalTrials.gov

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

PHASE1RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 27, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

CD19x22 CAR T

The CD19 CAR contains an FMC63 binding domain, a CD28 hinge/transmembrane/endodomain, and a CD3 zeta endodomain. The CD22 CAR contains the binding domain (m971), a CD8alpha hinge and transmembrane domain, a 41BB endodomain, and a CD3 zeta endodomain.

Trial Locations (1)

80045

RECRUITING

Children's Hospital Colorado, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER